A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT
Latest Information Update: 18 Aug 2021
At a glance
- Drugs Sildenafil (Primary)
- Indications Neonatal-disorders; Pulmonary hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 27 May 2021 Results published in the Journal of Pediatrics
- 08 Apr 2021 Results published in the European Clinical Trials Database Trial Registry
- 24 Nov 2020 This trial has been completed in Netherlands according to European Clinical Trials Database record.